Secondary Logo

Journal Logo

Most Popular Articles

Cellular and Humoral Immune Responses Induced by an HLA Class I–restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer

Nishida, Sumiyuki; Morimoto, Soyoko; Oji, Yusuke; More

Journal of Immunotherapy. 45(1):56-66, January 2022.

Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib

Qin, Jim S.; Johnstone, Timothy G.; Baturevych, Alex; More

Journal of Immunotherapy. 43(4):107-120, May 2020.

Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment

Diem, Stefan; Fässler, Mirjam; Bomze, David; More

Journal of Immunotherapy. 42(3):89-93, April 2019.

Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers

Wang, Xueyin; Sandberg, Mark L.; Martin, Aaron D.; More

Journal of Immunotherapy. 44(8):292-306, October 2021.

Generation of Antitumor T Cells For Adoptive Cell Therapy With Artificial Antigen Presenting Cells

Shrestha, Bishwas; Zhang, Yongliang; Yu, Bin; More

Journal of Immunotherapy. 43(3):79-88, April 2020.

First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient

Pollack, Seth M.; Lu, Hailing; Gnjatic, Sacha; More

Journal of Immunotherapy. 40(8):302-306, October 2017.

Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity

Fotin-Mleczek, Mariola; Duchardt, Katharina M.; Lorenz, Christina; More

Journal of Immunotherapy. 34(1):1-15, January 2011.

Strictly Target Cell-dependent Activation of T Cells by Bispecific Single-chain Antibody Constructs of the BiTE Class

Brischwein, Klaus; Parr, Larissa; Pflanz, Stefan; More

Journal of Immunotherapy. 30(8):798-807, November-December 2007.

Eosinophilic Vasculitis and Arteritic Anterior Ischemic Optic Neuropathy Associated With Anti-PD-L1 Therapy

Berry, Ella C.; Mullany, Sean; Quinlivan, Alannah; More

Journal of Immunotherapy. 45(1):51-55, January 2022.

Rapid Identification and Evaluation of Neoantigen-reactive T-Cell Receptors From Single Cells

Paria, Biman C.; Levin, Noam; Lowery, Frank J.; More

Journal of Immunotherapy. 44(1):1-8, January 2021.

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

Morgan, Richard A.; Chinnasamy, Nachimuthu; Abate-Daga, Daniel; More

Journal of Immunotherapy. 36(2):133-151, February-March 2013.

Association Between Body Mass Index and Survival Outcomes In Patients Treated With Immune Checkpoint Inhibitors: Meta-analyses of Individual Patient Data

Nie, Run-Cong; Chen, Guo-Ming; Wang, Yun; More

Journal of Immunotherapy. 44(9):371-375, November/December 2021.

Antitumor Activity of an EpCAM/CD3-bispecific BiTE Antibody During Long-term Treatment of Mice in the Absence of T-cell Anergy and Sustained Cytokine Release

Amann, Maria; dÁrgouges, Sandrine; Lorenczewski, Grit; More

Journal of Immunotherapy. 32(5):452-464, June 2009.

Chimeric Antigen Receptor–modified T Cells Repressed Solid Tumors and Their Relapse in an Established Patient-derived Colon Carcinoma Xenograft Model

Teng, Ruidi; Zhao, Jingjing; Zhao, Yiding; More

Journal of Immunotherapy. 42(2):33-42, February/March 2019.

Early Experience With CliniMACS Prodigy CCS (IFN-gamma) System in Selection of Virus-specific T Cells From Third-party Donors for Pediatric Patients With Severe Viral Infections After Hematopoietic Stem Cell Transplantation

Kállay, Krisztián; Kassa, Csaba; Réti, Marienn; More

Journal of Immunotherapy. 41(3):158-163, April 2018.

The Role of Extracellular Spacer Regions in the Optimal Design of Chimeric Immune Receptors: Evaluation of Four Different scFvs and Antigens

Guest, Ryan D; Hawkins, Robert E; Kirillova, Natalia; More

Journal of Immunotherapy. 28(3):203-211, May-June 2005.

A Clinical Development Paradigm for Cancer Vaccines and Related Biologics

Hoos, Axel; Parmiani, Giorgio; Hege, Kristen; More

Journal of Immunotherapy. 30(1):1-15, January 2007.

Genetic Engineering of Murine CD8+ and CD4+ T Cells for Preclinical Adoptive Immunotherapy Studies

Kerkar, Sid P.; Sanchez-Perez, Luis; Yang, Shicheng; More

Journal of Immunotherapy. 34(4):343-352, May 2011.

Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

Petrelli, Fausto; Grizzi, Giulia; Ghidini, Michele; More

Journal of Immunotherapy. 43(1):1-7, January 2020.

Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy

Hollyman, Daniel; Stefanski, Jolanta; Przybylowski, Mark; More

Journal of Immunotherapy. 32(2):169-180, February-March 2009.

Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB

Dudal, Sherri; Hinton, Heather; Giusti, Anna M.; More

Journal of Immunotherapy. 39(7):279-289, September 2016.

DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection

Chandra, Janin; Dutton, Julie L.; Li, Bo; More

Journal of Immunotherapy. 40(2):62-70, February/March 2017.

Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA

Lutterbuese, Ralf; Raum, Tobias; Kischel, Roman; More

Journal of Immunotherapy. 32(4):341-352, May 2009.

Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors

Mota, Jose Mauricio; Teo, Min Yuen; Whiting, Karissa; More

Journal of Immunotherapy. 44(7):248-253, September 2021.

PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer

Dulos, John; Carven, Gregory J.; van Boxtel, Susan J.; More

Journal of Immunotherapy. 35(2):169-178, February-March 2012.

Long-term Overall Survival and Predictors in Anti–PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study

Naik, Girish S.; Buchbinder, Elizabeth I.; Cohen, Justine V.; More

Journal of Immunotherapy. 44(8):307-318, October 2021.

A Novel CD19-directed Recombinant Bispecific Antibody Derivative With Enhanced Immune Effector Functions for Human Leukemic Cells

Kellner, Christian; Bruenke, Joerg; Stieglmaier, Julia; More

Journal of Immunotherapy. 31(9):871-884, November-December 2008.

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program

Gangadhar, Tara C.; Hwu, Wen-Jen; Postow, Michael A.; More

Journal of Immunotherapy. 40(9):334-340, November/December 2017.

Cytokine Maturation Followed by CD40L mRNA Electroporation Results in a Clinically Relevant Dendritic Cell Product Capable of Inducing a Potent Proinflammatory CTL Response

Calderhead, David M.; DeBenedette, Mark A.; Ketteringham, Helen; More

Journal of Immunotherapy. 31(8):731-741, October 2008.

CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis

Fischer, Jeannette; Paret, Claudia; El Malki, Khalifa; More

Journal of Immunotherapy. 40(5):187-195, June 2017.

Expanded Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma Have Tumor-specific Function

Mullinax, John E.; Hall, MacLean; Beatty, Matthew; More

Journal of Immunotherapy. 44(2):63-70, February/March 2021.